Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM2V4EO)

Drug Name

BCMA CART and huCART19 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell maturation protein (TNFRSF17)	TTZ3P4W	TNR17_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
B-lymphocyte surface antigen B4 (CD19)	DTT	CD19	5.758	6.211	6.083	5.396

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Multiple myeloma

ICD Disease Classification

2A83

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
B-lymphocyte surface antigen B4 (CD19)	DTT	CD19	2.33E-24	-1.06	-1.33

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma